Helus Pharma Inc. (CYBN) Financial Statements
Helus Pharma Inc. (CYBN) files with the U.S. Securities and Exchange Commission under CIK 0001833141. 10KGenie shows its annual statements from SEC filings.
Key Figures, Fiscal Year 2025
- Net Income
- -113.14 million CAD
- Total Assets
- 258.62 million CAD
- Net Cash from Operations
- -101.30 million CAD
Fiscal year ended Mar 31, 2025. Latest periodic SEC filing: Jul 1, 2025. Source: SEC filings (EDGAR XBRL). Amounts in CAD.
Open the full financial statements for CYBN in 10KGenie
Data from SEC EDGAR filings. 10KGenie is not affiliated with the SEC. SEC Filing History